258 related articles for article (PubMed ID: 6968908)
1. Animal model for immune dysfunction associated with adenosine deaminase deficiency.
Tedde A; Balis ME; Ikehara S; Pahwa R; Good RA; Trotta PP
Proc Natl Acad Sci U S A; 1980 Aug; 77(8):4899-903. PubMed ID: 6968908
[TBL] [Abstract][Full Text] [Related]
2. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
3. Effects of deoxycoformycin in mice. III. A murine model reproducing multi-system pathology of human adenosine deaminase deficiency.
Ratech H; Hirschhorn R; Thorbecke GJ
Am J Pathol; 1985 Apr; 119(1):65-72. PubMed ID: 3872599
[TBL] [Abstract][Full Text] [Related]
4. Metabolic abnormalities of human adenosine deaminase deficiency reproduced in the mouse by 2'-deoxycoformycin, and adenosine deaminase inhibitor.
Ratech H; Thorbecke GJ; Hirschhorn R
Clin Immunol Immunopathol; 1981 Oct; 21(1):119-27. PubMed ID: 6268339
[No Abstract] [Full Text] [Related]
5. Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse.
Nicholson JK; Gordon DS; McDougal JS
Cell Immunol; 1983 Jul; 79(2):320-33. PubMed ID: 6347398
[TBL] [Abstract][Full Text] [Related]
6. The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat.
Barton RW
Cell Immunol; 1985 Oct; 95(2):297-310. PubMed ID: 3876160
[TBL] [Abstract][Full Text] [Related]
7. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
8. Adenosine deaminase and immune dysfunction. Biochemical correlates defined by molecular analysis throughout a disease course.
Coleman MS; Danton MJ; Philips A
Ann N Y Acad Sci; 1985; 451():54-65. PubMed ID: 3878121
[No Abstract] [Full Text] [Related]
9. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
Smith CM; Henderson JF
Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
[TBL] [Abstract][Full Text] [Related]
10. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
[TBL] [Abstract][Full Text] [Related]
11. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
Agarwal RP
Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
[No Abstract] [Full Text] [Related]
12. Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2'-deoxycoformycin.
Checkik BE; Perets A; SenGupta S; Fernandes B
J Natl Cancer Inst; 1983 Nov; 71(5):999-1010. PubMed ID: 6358608
[TBL] [Abstract][Full Text] [Related]
13. The effects of ADA inhibition on B cell differentiation in the rat.
Barton RW
Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
[No Abstract] [Full Text] [Related]
14. Effect of ADA deficiency on cultured murine thymus transplantation.
Hong R; Horowitz SD; Fortman C; Martin DW
Clin Immunol Immunopathol; 1982 May; 23(2):448-58. PubMed ID: 6980759
[No Abstract] [Full Text] [Related]
15. ATP depletion as a consequence of adenosine deaminase inhibition in man.
Siaw MF; Mitchell BS; Koller CA; Coleman MS; Hutton JJ
Proc Natl Acad Sci U S A; 1980 Oct; 77(10):6157-61. PubMed ID: 6969403
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
17. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
18. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
19. Specificity of 2'-deoxycoformycin inhibition of adenosine metabolism in intact human skin fibroblasts.
Holland MJ
Res Commun Chem Pathol Pharmacol; 1986 Mar; 51(3):311-24. PubMed ID: 3486439
[TBL] [Abstract][Full Text] [Related]
20. Interleukin 2 liberation and absorption capacities of rat T lymphocytes in conditions of severe adenylic nucleotide pool depletion due to adenosine deaminase deficiency.
Thuillier L; Arenzana-Seisdedos F; Pérignon JL; Munier A; Hamet M; Cartier PH
Immunopharmacology; 1985 Oct; 10(2):89-97. PubMed ID: 3877709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
